Risk communication: The Avandia case, a pilot study

Expert Review of Clinical Pharmacology

Volumn 3, Issue 1, 2010, Pages 31-41

  Lofstedt, Ragnar ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Avandia ; Drug safety; Risk communication; US FDA

Indexed keywords

PIOGLITAZONE; ROSIGLITAZONE;

CARDIOVASCULAR RISK; DEATH; DRUG CONTROL; DRUG EFFICACY; DRUG INDUSTRY; DRUG SAFETY; HEART INFARCTION; HUMAN; MASS MEDIUM; MEDICAL LITERATURE; NON INSULIN DEPENDENT DIABETES MELLITUS; PILOT STUDY; POLITICS; POSTMARKETING SURVEILLANCE; REVIEW; RISK BENEFIT ANALYSIS;

EID: 77949718903     PISSN: 17512433     EISSN: None     Source Type: Journal    
DOI: 10.1586/ecp.09.49     Document Type: Review

References (100)

1. DREAM (Diabetes Reduction Assessment with Ramipril and Rosiglitazone Medication) investigators. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised control trial. Lancet 368, 1096-1105 (2006).
2. Nissen S, Wolksi K. Effect of rosiglitazone on the risk of myocardial infarcation and death from cardiovascular causes. N. Engl. J. Med. 356 (24), 2457-2470 (2007).
3. Von Eschenbach AC. Statement Before the US House of Representatives Committee on Oversight and Government Reform, Hearing on FDA's Role in the Evaluation of Avandia's Safety. United States House of Representatives, Washington DC, USA 6 June 2007.
4. Jack A. Glaxo chief-in-waiting promises to diversify as shares tumble. Financial Times, London, UK, 8 February 2008.
5. Saul S. VA limits Glaxo drug widely used for diabetes. New York Times, NY, USA, 18 October 2007.
6. Bostrom A and Lofstedt RE. Communicating risks: wireless and hard wired. Risk Analysis 23, 241-248 (2003).
7. Breakwell GM. The Psychology of Risk. Cambridge University Press, Cambridge, UK (2007).
8. Eldridge J. Getting the Message: News, Truth and Power. Routledge, London, UK (1993).
9. Eldridge J, Reilly J. Risk and relativity: BSE and the British media. In: The Social Amplification of Risk. Pidgeon N, Kasperson R, Slovic P (Eds). Cambridge University Press, Cambridge, UK (2003).
10. Fischhoff B. Risk perception and communication unplugged: twenty years of progress. Risk Analysis 15, 137-145 (1995).
11. Fischhoff B. Public values in risk research. Ann. Am. Acad. Pol. Soc. Sci. 545, 75-84 (1996).
12. Leiss W. Three phases in the evolution of risk communication practice. Ann. Am. Acad. Pol. Soc. Sci. 545, 85-94 (1996).
13. McComas KA. Defining moments in risk communication research: 1996-2005. J. Health Comm. 11, 75-91 (2006).
14. National Research Council. Improving Risk Communication. National Academy Press, Washington DC, USA (1989).
15. National Research Council. Understanding Risk. National Academy Press, Washington, DC, USA (1996).
16. Slovic P. The Perception of Risk. Earthscan, London, UK (2000).
17. Kasperson RE, Palmlund I. Evaluating risk communication. In: Effective Risk Communication: The Role and Responsibility of Government and Non-Government Organisations. Covello V, McCallum DM, Pavlova MT (Eds). Plenum, NY, USA (1987).
18. Leiss W. In the Chamber of Risks: Understanding Risk Controversies. McGill- Queen's University Press, Montreal, Canada (2001).
19. Lofstedt RE. Science communication and the Swedish acrylamide alarm. J. Health Comm. 8, 407-430 (2003).
20. Powell D, Leiss W. Mad Cows and Mother's Milk: the Perils of Poor Risk Communication. McGill-Queen's University Press, Montreal, Canada (1997).
21. Kasperson RE, Renn O, Slovic P. The social amplification of risk: a conceptual framework. Risk Analysis 8, 177-187 (1988).
22. The Social Amplification of Risk. Pidgeon N, Kasperson RE, Slovic P (Eds). Cambridge University Press, Cambridge, UK (2003).
23. Lofstedt RE. Risk Management in Post Trust Societies. Palgrave/MacMillan, Basingstoke, UK (2005).
24. Pidgeon NF, Poortinga W, Walls J. Scepticism, reliance and risk management institutions: toward a conceptual model of critical trust. In: Trust in Cooperative Risk Management: Uncertainty and Scepticism in the Public Mind. Siegrist M, Earle TC, Gutscher H (Eds). Earthscan, London, UK (2007).
25. Poortinga W and Pidgeon NF. Trust in risk regulation: cause or consequence of the acceptability of GM food? Risk Analysis 25, 199-209 (2005).
26. Poortinga W and Pidgeon NF. Prior attitudes, salient value similarity, and dimensionality: toward an integrative model of trust in risk regulation. J. Appl. Soc. Psychol. 36, 1674-1700 (2006).
27. Renn O, Levine D. Credibility and trust in risk communication. In: Communicating Risks to the Public: International Perspectives. Kasperson RE, Stallen PJ (Eds). Kluwer, Amsterdam, The Netherlands 175-218 (1991).
28. Siegrist M, Earle TC, Gutscher H. Trust in Cooperative Risk Management: Uncertainty and Scepticism in the Public Mind. Earthscan, London, UK (2007).
29. Slovic P. Perceived risk, trust and democracy. Risk Analysis 13, 675-682 (1993).
30. Fischhoff B. Need to Know: Analytical and Psychological Criteria. Roger Williams University Law Review 6, 237-1221 (2000).
31. Flynn R, Ballaby P. Risk and the Public Acceptance of New Technologies. Palgrave/ Macmillan, Basingstoke, UK (2007)
32. Grassley C. Introduction of the Food and Drug Administration Act of 2007 (S.468) and Fair Access to Clinical Trials Act of 2007 (S.467). US Congress, Washington, DC, USA (2007).
33. Ignoring the warnings again? New York Times NY, USA, 25 May 2007.
34. Misdirected studies on Avandia. New York Times NY, USA, 12 June 2007.
35. Misbin RI. Medical Officer's review of New Drug Application-21-071- Rosiglitazone (Avandia). Food and Drug Administration, Rockville, MD, USA (1999).
36. Jenkins J. Sworn Testimony to US House of Representatives' Committee on Oversight and Government Reform Hearing on FDA's Role in the Evaluation of Avandia's Safety. US Congress, Washington DC, USA (2007).
37. Kahan SE et al. 2006. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. (ADOPT study group). N. Engl. J. Med. 355, 2427-2443 (2006).
38. Home PD, Pocock SJ, Beck-Nielsen H et al. 2006. Rosiglitazone evaluated for cardiac outcomes and regulation of glycamia in diabetes (RECORD): study design and protocol. Diabetologia 48, 1726-1735 (2006).
39. Home PD, Pocock SJ, Beck-Nielsen et al. Rosiglitazone evaluated for cardiovascular outcomes-an interim analysis. N. Eng. J. Med. 357, 28-38 (2007).
40. Drazen JM, Morrisey S, Curfman GD. Rosiglitazone - continued uncertainty about safety. N. Engl. J. Med. 357, 63-64 (2007).
41. Nathan DM. Rosiglitazone and cardiotoxicity-weighing the evidence. N. Engl. J. Med. 357, 64-66 (2007).
42. Psaty BM, Furberg CD. The record of Rosiglitazone and the risk of myocardial infarcation. N. Engl. J. Med. 357, 67-69 (2007).
43. Home PD, Pocock SJ, Beck-Nielsen H et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for Type 2 diabetes (RECORD): a multicentre, open-label trial. Lancet 373(9681), 2125-2135 (2009).
44. Herper M. Glaxo fails to learn lesson of Avandia. Forbes, New York, NY, USA, 5 June 2009.
45. Retnakaran R, Zinman B. Thiazolidinediones and clinical outcomes in Type 2 diabetes. Lancet 373(9681), 2088-2090 (2009).
46. Buse JB. Letter to Commissioner J. Heeney. Citizen's Petition to Immediately Require Class Labelling for the Diabetes Drug Troglitazone (Rezulin), Rosiglitazone (Avandia), and Pioglitazone (Actos). UNC Health Care Diabetes Centre, Chapel Hill, NC, USA 15 March (2000).
47. Buse JB. Sworn Testimony to US House of Representatives' Committee on Oversight and Government Reform Hearing on FDA's Role in the Evaluation of Avandia's Safety. US Congress, Washington DC, USA, 6 June 2007.
48. Nissen S. The DREAM trial. Lancet 268, 2049 (2006).
49. Burgess A. Cellular Phones, Public Fears and a Culture of Precaution. Cambridge University Press, Cambridge, UK (2004).
50. Institute of Medicine. The Future of Drug Safety: Promoting and Protecting the Health of the Public. National Academies Press, Washington, DC, USA (2006).
51. Morgan MG, Fischhoff B, Bostrom A, Altman C. Risk Communication: a Mental Models Approach. Cambridge University Press, NY USA (2002).
52. Gottlieb S. Journalistic malpractice. Wall Street Journal NY, USA 29 May 2007.
53. Economist. Special report - the drugs industry: an overdose of bad news. Economist London, UK, 19 March 2005.
54. Harris Interactive. The FDA's Reputation is Under Assault. Harris Interactive Market Research, Rochester, NY, USA (2006).
55. Harris Interactive. Confidence in FDA Hits new Low, According to WSJ.com? Harris interactive study. Harris Interactive Market Research, Rochester, NY, USA (2008).
56. US FDA. The Future of Drug Safety- Promoting and Protecting the Health of the Public-FDA's Response to the Institute of Medicine's 2006 Report. US FDA, Rockville, MD, USA (2007).
57. Bass A. Side effects: A Prosecutor, a Whistleblower, and Best Selling Antidepressant on Trial. Algonquin Books of Chapel Hill, Chapel Hill, NC, USA (2008).
58. Meier B. Glaxo begin posting drug trial results. New York Times NY, USA, 1 September 2004.
59. Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective Cox-2 inhibitors. JAMA 286, 954-959 (2001).
60. Mukherjee D, Nissen SE, Topol EJ. Cox-2 inhibitors and cardiovascular risk: we defend our data and suggest caution. Cleveland Clinic J. Med. 68, 963-964 (2001).
61. Whalen J. In Europe, warning on Avandia is old news. Wall Street Journal, NY, USA, 23 May 2007.
62. Psaty B. Sworn Testimony before the US House of Representatives' House Committee on Oversight and Government Reform. Hearing on FDA's role in the evaluation of Avandia's safety. US Congress, Washington DC, USA, 6 June 2007.
63. Psaty B, Furberg CD. Rosiglitazone and cardiovascular risk. N. Engl. J. Med. 356, 2522-2524 (2007).
64. Buse JB. Fax to Tadataka Yamada, Smith Klein Beecham. UNC Health Care Diabetes Care Center, Chapel Hill, NC, USA (2002).
65. Slauoui M. Sworn Testimony to US House of Representatives' Committee on Oversight and Government Reform Hearing on FDA's Role in the Evaluation of Avandia's Safety. US Congress, Washington, DC, USA, 6 June 2007.
66. United States Senate Committee on Finance. The Intimidation of Dr. John Buse and the Diabetes Drug Avandia. United States Senate, Committee on Finance, Washington, DC, USA (2007).
67. Niisen S. Sworn testimony before US House of Representatives Committee on Oversight and Government Reform, Hearing on FDA's Role in the Evaluation of Avandia's Safety. US Congress, Washington, DC, USA 6 June 2007.
68. Waxman HA. Statement of Rep. Henry A. Waxman, Chairman, US House of Representatives Committee on Oversight and Government Reform, Hearing on FDA's role in the evaluation of Avandia's safety. US Congress, Washington, DC, USA, 6 June 2007.
69. Fischhoff B. A guide to controversy. Appendix C. In: The National Research Council, Improving Risk Communication. National Academy Press, Washington, DC, USA 211-319 (1989).
70. Fischhoff B. Risk perception and communication. In: Oxford Textbook on Public Health, Fifth Edition. Detels R, Beaglehole R, Lansang MA, Gulliford M. (Eds). Oxford University Press, Oxford, UK 941-952 (2009).
71. Abraham J. The pharmaceutical industry as a political player. Lancet 360, 1498-1502 (2002).
72. Abraham J, Lews G. Secrecy and transparency of medicines licensing in the EU. Lancet 352, 480-482 (1998).
73. European Commission. European Governance: A White Paper (COM 2001 428 Final). Brussels, European Commission (2001).
74. UK Strategy Unit. Risk: Improving Government's Capability to Handle Risk and Uncertainty. Strategy Unit, Stationary Office, London, UK (2002).
75. Gutman A, Thompson D. Why Deliberative Democracy? Princeton University Press, Princeton, NJ, USA.
76. Hood C, Rothstein H, Baldwin R. The Government of Risk: Understanding Risk Regulation Regimes. Oxford University Press, Oxford, UK (2001).
77. Lamble S. Freedom of information, a Finnish clergyman's gift to democracy. Freedom of Information Review 97, 2-8 (2002).
78. Shrader-Frechette K. Risk and Rationality: Philosophical Foundations for Populist Reforms. University of California Press, Berkeley, CA, USA (1991).
79. Transparency: The Key to Better Governance? Proceedings of the British Academy 135. Hood C, Heald D (Eds). Oxford University Press, Oxford, UK (2006).
80. O'Neil O. A Question of Trust: The BBC Reith Lectures 2002. Cambridge University Press, Cambridge (2002).
81. Barriaux M. Glaxo chief curses media and issues profit warning. Guardian London, UK, 8 February 2008.
82. Horton R. MMR Science and Fiction: Exploring the vaccine crisis. Granta, London, UK (2004).
83. Davis T. Questioning Witnesses at the US House of Representatives' Committee on Oversight and Regulatory Reform Hearing on FDA's Role in the Evaluation of Avandia's Safety. US Congress, Washington, DC, USA 6 June 2007.
84. Meier M. For drug makers, a downside to full disclosure. New York Times NY, USA, 23 May 2007.
85. Avorn J. Paying for drug approvals-who is using whom? N. Engl. J. Med. 356, 1697-1700 (2007)
86. McClellan M. Drug safety reform at the FDA-pendulum swing or systematic improvement? N. Engl. J. Med. 356, 1700-1702 (2007)
87. Demortain D. From drug crises to regulatory change: The mediation of expertise. Health Risk Soc. 10, 37-51 (2008).
88. Fischhoff B. Why (cancer) risk communication can be hard. J. Natl Cancer Inst. 25, 7-13 (1999).
89. Fischhoff B, Downs J, Bruine de Bruin W. Adolescent vulnerability: a framework for behavioural interventions. Appl. Prev. Psychol. 7, 77-94 (1998).
90. Fischhoff B, Bostrom A, Quadrel MJ. Risk perception and communication. In: Oxford Text Book of Public Health. Detels R, McEwen J, Omenn O (Eds). Oxford University Press, Oxford, UK 1105-1123 (2002).
91. Fischhoff B, Eggers S. Mental models of warning decisions: identifying and addressing information needs. In: The Handbook of Warnings. Wolgalter M (Ed.). Lawrence Erlbaum Associates, Hillsdale, NJ, USA 279-287 (2006).
92. Albin C. The role of fairness in negotiation. Negotiation J. 9, 223 (1993).
93. Renn O, Webler T, Wiedemann P. Fairness and Competence in Citizen Participation. Kluwer, Dordrecht, The Netherlands (1995).
94. Renn O, Webler T, Kastenholz H. Procedural and substantive fairness in landfill siting. Risk: Health, Safety and Environment 7, 145-168 (1996).
95. Viscusi WK. Rational Risk Policy. Oxford University Press, Oxford, UK (1998).
96. UK House of Commons Health Committee. The Influence of the Pharmaceutical Industry. The Stationary Office, London, UK, 1 (2005).
97. IPSOS-MORI. Risks and Benefits of Medicines and Medical Devices-Perceptions, communication and regulation - Report on Quantitative Research Among the General Public. IPSOS-MORI, London, UK (2006).
98. IPSOS-MORI. Risks and Benefits of Medicines and Medical Devices-Perceptions, Communication and Regulation-Report on Qualitative Research Among the General Public. IPSOS-MORI, London, UK (2006).
99. Gawande A. Better: A Surgeon's Notes on Performance. Metropolitan Books, New York, NY, USA (2007).
100. Harrabin R, Coote A, Allen J. Health in the News: Risk, Reporting and Media Influence. King's Fund, London, UK (2003)